Immatics (IMTX) EBT Margin (2019 - 2026)

Immatics (IMTX) posted EBT Margin of 179.97% for Q4 2025, up 81.58% sequentially from 976.9% in Q3 2025, and down 25689.0% YoY from N/an in Q4 2024.

Analysis

Immatics (IMTX) EBT Margin (2019 - 2026) Analysis & Trends

Immatics has reported EBT Margin for 7 years, with the latest figure at 179.97% in Q4 2025.

Quarterly EBT Margin fell 25689.0% year-over-year to 179.97% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 415.69% (down 42906.0% YoY) and the FY2025 annual result came in at 411.13%, down 42483.0% from the prior year.
EBT Margin grew to 179.97% in Q4 2025 per IMTX's latest filing, from 976.9% in the prior quarter.
Over five years, EBT Margin peaked at 83.24% in Q1 2022 and troughed at 1506.21% in Q2 2025.
A 5-year average of 266.86% and a median of 149.77% in 2022 frame the typical range for EBT Margin.
The sharpest annual moves came in 2021 and 2025: EBT Margin jumped 166083 bps in 2021, then plunged 141102 bps in 2025.
Over 5 years, EBT Margin stood at 106.74% in 2021, then jumped by 74 bps to 27.66% in 2022, then sank by 494 bps to 164.24% in 2023, then surged by 147 bps to 76.92% in 2024, then plunged by 334 bps to 179.97% in 2025.
According to Business Quant data, EBT Margin over the past three periods registered 179.97%, 976.9%, and 1506.21% for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	35.61%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	35.78%
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-528.97%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	18.33%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	13.77%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	12.09%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-2.67%
10	Immatics	1.17 Bn	711.21 Mn	-	-686.42%

Historic Data

Download Data